Case Report

A Case of Nonuremic Calciphylaxis in a Caucasian Woman

Bonnie Fergie,1 Nishant Valecha,2 and Andrew Miller1

1Canberra Hospital, ACT Health, Canberra, ACT, Australia
2Woden Dermatology, Phillip, ACT, Australia

Correspondence should be addressed to Bonnie Fergie; bonniefergie@gmail.com

Received 19 October 2016; Accepted 14 November 2016; Published 16 January 2017

Academic Editor: Jacek Cezary Szepietowski

Copyright © 2017 Bonnie Fergie et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

We report a case of nonuremic calcific arteriolopathy (NUCA) in an 82-year-old Caucasian woman from rural Australia. The patient had no history of kidney disease or dialysis. NUCA is rare disease suspected on cutaneous and clinical features and diagnosed by characteristic findings on skin biopsy and vasculature imaging. Calcification induced microvascular occlusion in the absence of renal failure may not be immediately apparent. Clinical suspicion and appropriate investigations are essential for making a diagnosis. A diagnosis of NUCA may be missed given the rarity of the disease, and dermatologists and patients alike would benefit from a greater awareness of this disease.

1. Introduction

Calcific uremic arteriolopathy (CUA), otherwise termed calciphylaxis, characteristically arises in the setting of end stage renal failure and hyperparathyroidism. Calcific arteriolopathy in the setting of normal renal function is a rare entity termed nonuremic calcific arteriolopathy (NUCA). Both NUCA and CUA are caused by microvascular occlusion secondary to calcium deposition in the vessels of the skin and subcutaneous fat. Given the high morbidity and mortality associated with NUCA, recognition and timely diagnosis are essential for patient management.

2. Case

An 82-year-old woman from rural Australia admitted to hospital for an exacerbation of congestive cardiac failure (CCF) developed intensely painful, flesh colored, subcutaneous nodules on both lower legs and left thigh on a background of livedo racemosa. The nodules coincided with a creatinine rise from 96 μmol/L to 120 μmol/L (Table 1) following aggressive diuresis with furosemide for CCF management. Furosemide was subsequently reduced and renal function normalized. Over the subsequent weeks the nodules ulcerated and took on a serpiginous form.

The patient’s comorbidities were rheumatoid arthritis, atrial fibrillation, chronic obstructive pulmonary disease, mitral valve replacement (bovine), hypertension, and hypercholesterolemia. Her medications were furosemide, methotrexate 5 mg/week, prednisolone 2.5 mg/day, spironolactone, oxycodone, rabeprazole, potassium, warfarin, salbutamol, budesonide, and formoterol. She had been on the same dose of warfarin for many years and had never smoked cigarettes.

Physical examination showed an afebrile, haemodynamically stable, elderly woman in severe pain from the leg ulcerations. Multiple deep serpiginous ulcerations with overlying necrotic eschars and surrounding macular erythema were present on both lower legs (Figure 1). A new subcutaneous flesh colored nodule with surrounding erythema was present on her left lateral thigh. Livedo racemosa was present on her upper and lower legs bilaterally.

Deep wedge incisional biopsies taken from the left thigh nodule and calf showed panlobular infarction of subcutaneous fat with extensive mural calcification of small and medium sized vessels within the pannus, with luminal occlusion (Figure 2). The left calf showed epidermal and dermal necrosis and ulceration. No features of vasculitis were seen. Direct immunofluorescence was negative. Laboratory investigations (Table 1) showed an elevated intact parathyroid hormone (PTH) 17.7 pmol/L, low urine calcium 0.9 mmol/24 hr, and the aforementioned creatinine elevation. Serum calcium, phosphate, vitamin D, and urea were normal. Plain X-rays of the legs showed extensive vascular
Table 1: Blood results.

| Test                   | 02.08.2015 | 21.09.2015 | Normal range          |
|------------------------|------------|------------|-----------------------|
| Haemoglobin            | 138        | 129        | 115–160 g/L           |
| White cell count       | 7.0        | 7.4        | 4–11 × 10⁹            |
| Platelets              | 251        | 220        | 150–400 × 10⁹         |
| Neutrophils            | 5.26       | 6.02       | 1.8–7.5 × 10⁹         |
| Urea                   | 6.7        | 12.6       | 2.5–7.5 mmol/L        |
| Creatinine             | 96         | 120        | 45–90 μmol/L          |
| GFR est                | 48         | 36         | >90 Mls/min           |
| Glucose                | 5.0        | 6.6        | 3.5–5.5 mmol/L        |
| Osm-calc               | 291        | 290        | 280–300 mOsm/kg       |
| Bilirubin total        | 25         | 23         | 2–20 μmol/L           |
| ALT                    | 14         | 29         | 9–33 U/L              |
| Alkaline phosphatase   | 101        | 140        | 30–110 U/L            |
| New GGT                | 295        | 502        | 9–56 g/L              |
| Albumin                | 41         | 43         | 33–50 g/L             |
| ESR                    | 32         | 43         | 1–40 mm/hr            |
| CRP                    | 7.3        |            | <6 Mg/L               |
| ACE level (Buhlmann)   | 49.8       |            | 20–70 U/L             |
| Calcium                | 2.36       |            | 2.1–2.6 mmol/L        |
| Corrected calcium      | 2.42       |            | 2.1–2.6 mmol/L        |
| Phosphate              | 1.39       |            | 0.75–1.50 mmol/L      |
| Intact serum PTH       | 17.7       |            | 1.6–7.2 pmol/L        |
| 25-OH vitamin D        | 82         |            | <60 nmol/L            |
| Urinary Creatinine     | 5.7        |            | 5.3–15.9 mmol/24 h    |
| Urinary calcium        | 0.9        |            | 2.5–7.5 mmol/24 h     |
| Cold agglutinin        | Negative   |            |                       |
| Cryoglobulin           | Negative   |            |                       |
| C3                     | 1.58       |            | 0.75–1.61 g/L         |
| C4                     | 0.44 H     |            | 0.13–0.40 g/L         |
| IgG                    | 5.3        |            | 6.5–15.2 g/L          |
| IgA                    | 1.06       |            | 0.76–3.89 g/L         |
| IgM                    | 0.6        |            | 0.3–2.3 g/L           |
| ANA speckled           | 1:80       |            | Negative              |
| ENA                    | Negative   |            | <30 AU/mL             |
| dsDNA                  | 5          | <40 IU/mL  |                       |
| ANCA                   | Atypical   |            | Negative              |
| MPO ANCA               | Negative   |            | Negative              |
| PR3 ANCA               | Negative   |            | Negative              |
| Globulins              | Normal     | Normal     |                       |

calcification bilaterally throughout the whole legs including the iliac, femoral, popliteal, and tibial vessels (Figure 3). Abdominal ultrasound showed areas of bilateral medullary nephrocalcinosis. Thyroid ultrasound showed a colloidal cyst; the parathyroid glands were not visualized. Nuclear imaging of the parathyroid glands showed no abnormality. These clinical, radiological, and histopathological findings were consistent with a diagnosis of NUCA.

The patient was commenced on doxycycline 50 mg/day and was given an infusion of Zoledronic acid 5 mg. Warfarin was ceased and the patient was commenced on rivaroxaban.

Figure 1: Necrotic ulceration on lower legs.

Figure 2: Biopsy left calf, illustrating arteriolar calcification in subcutis.

Figure 3: X-ray illustrating calcification of the femoral and popliteal vessels.

There were no new nodules 6 months after the initial episode and the established erosions were healing slowly.

3. Discussion

NUCA is a rare obstructive vasculopathy caused by calcium deposition within the lumen of small and medium sized blood vessels. In the absence of renal failure, identified risk factors are hypercoagulable states, malignancy, hyperparathyroidism, connective tissue disease, corticosteroids, vitamin D deficiency, calcium based phosphate binders, warfarin, obesity, and diabetes [1–5]. This patient’s risk factors...
were gender, hyperparathyroidism, connective tissue disease, corticosteroid, and warfarin use. Although risk factors for NUCA have been identified the pathogenesis remains poorly understood.

In CUA chronic renal failure causes excess phosphate, which binds with calcium in the blood resulting in blood vessel damage. Reduced vitamin D levels result in increased PTH production. As bones become resistant to PTH the parathyroid glands enlarge to produce more PTH and calcium levels in the blood increase. Although the initial mechanism resulting in calcium deposition in NUCA is not as well characterised as CUA a final common pathway for both CUA and NUCA has been proposed. This pathway involves elevated nuclear factor kB, leading to vascular calcification and thrombosis [4]. Via this pathway, chronic inflammation, impaired liver function, estrogens, parathyroid hormone abnormalities, warfarin, and glucocorticoids may all contribute to the disease.

In this case, given the normal renal function, calcium, phosphate, and vitamin D levels, the elevated PTH represents tertiary hyperparathyroidism. The initial creatinine rise was attributed to hypovolemia caused by aggressive CCF management. Satellite purpuric ulcerations with central overlying necrosis crusts, present in this case, typify the clinical lesions of NUCA. Livedo reticularis or racemosa is usually present on the legs and may precede ulcerations. Clinicopathological correlation is essential for a diagnosis of NUCA.

The characteristic histological features of NUCA, as evident in this case, are calcification of small-medium sized cutaneous vessels, intimal fibrosis, intravascular thrombi, and diffuse calcification of small capillaries in the fat. There may be calcification of adipocytes. Epidermal and dermal ulceration give rise to the typical clinical features of NUCA. Investigations such as plain film X-rays or bone scintigraphy can show arteriolar calcification which may aid diagnosis or monitoring of treatment effects [6].

The management of NUCA involves elimination of identifiable precipitants, adequate analgesia, and early treatment. Meticulous wound management decreases infection risk, and surgical debridement may be warranted. Recent research has suggested that changing warfarin to low molecular weight heparin may be beneficial [5]. Rivaroxaban rather than low molecular weight heparin replaced warfarin in this case due to atrial fibrillation. Other reported treatments are calcimimetic agents, bisphosphonates, hyperbaric oxygen, low dose tissue plasminogen activator, and doxycycline [7]. There is limited evidence for intravenous sodium thiosulfate for its antioxidative properties and ability to increase calcium solubility in NUCA [8].

4. Conclusion

This rare case of NUCA in an 82-year-old Caucasian woman coincided with her hospitalization for the management of her CCF. Her risk factors were gender, connective tissue disease, hyperparathyroid level, glucocorticoid use, and warfarin use. Clinical, histological, and radiological evidence were consistent with a diagnosis of NUCA with no sinister precipitating factors found. The patient improved with meticulous wound care, analgesia, doxycycline 50 mg/day, Zoledronic acid 5 mg, and warfarin cessation. Given the rarity of the disease dermatologists and patients alike would benefit from a greater awareness of NUCA.

Abbreviation List
CUA: Calcific uremic arteriolopathy
CCF: Congestive cardiac failure
NUCA: Nonuremic calcific arteriolopathy
PTH: Parathyroid hormone.

Consent
Patient consent was obtained prior to writing the article.

Competing Interests
The authors have no conflict of interests to declare.

Authors’ Contributions
All authors are significant contributors and have approved the final copy of this article.

References
[1] S. U. Nigwekar, M. Wolf, R. H. Sterns, and J. K. Hix, “Calciphylaxis from nonuremic causes: a systematic review,” Clinical Journal of the American Society of Nephrology, vol. 3, no. 4, pp. 1139–1143, 2008.
[2] J. Panuncialman and V. Falanga, “Unusual causes of cutaneous ulceration,” The Surgical Clinics of North America, vol. 90, no. 6, pp. 1161–1180, 2010.
[3] R. H. Weenig, L. D. Sewell, M. D. P. Davis, J. T. McCarthy, and M. R. Pittelkow, “Calciphylaxis: natural history, risk factor analysis, and outcome,” Journal of the American Academy of Dermatology, vol. 56, no. 4, pp. 569–579, 2007.
[4] R. H. Weenig, “Pathogenesis of calciphylaxis: how Selye to nuclear factor 𝜅-B,” Journal of the American Academy of Dermatology, vol. 58, no. 3, pp. 458–471, 2008.
[5] R. J. Harris and T. G. Cropley, “Possible role of hypercoagulability in calciphylaxis: review of the literature,” Journal of the American Academy of Dermatology, vol. 64, no. 2, pp. 405–412, 2011.
[6] S. Paul, C. A. Rabito, P. Vedak, S. U. Nigwekar, and D. Kroshinsky, “The role of bone scintigraphy in the diagnosis of calciphylaxis,” JAMA Dermatology, 2015.
[7] C. Vedvys, L. S. Winterfield, and R. A. Vleugels, “Calciphylaxis: a systematic review of existing and emerging therapies,” Journal of the American Academy of Dermatology, vol. 67, no. 6, pp. e253–e260, 2012.
[8] V. M. Smith, T. Oliphant, M. Shareef, W. Merchant, and S. M. Wilkinson, “Calciphylaxis with normal renal function: treated with intravenous sodium thiosulfate,” Clinical and Experimental Dermatology, vol. 37, no. 8, pp. 874–878, 2012.